Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
Previous Symbol
CUSIP30161Q10
Phone650-837-7000
Debt
Debt-to-Equity Ratio0.01
Current Ratio8.66
Quick Ratio8.54
Price-To-Earnings
Trailing P/E Ratio34.78
Forward P/E Ratio13.56
P/E Growth1.06
Sales & Book Value
Annual Sales$452.48 million
Price / Sales11.65
Cash Flow$0.5382 per share
Price / Cash32.76
Book Value$0.96 per share
Price / Book18.36
Profitability
EPS (Most Recent Fiscal Year)$0.51
Net Income$154.22 million
Net Margins49.53%
Return on Equity55.71%
Return on Assets43.79%
Miscellaneous
Employees372
Outstanding Shares298,980,000
Market Cap$5.36 billion
OptionableOptionable
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) announced its earnings results on Thursday, November, 1st. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.19 by $0.22. The biotechnology company had revenue of $225.40 million for the quarter, compared to analysts' expectations of $174.14 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business's revenue for the quarter was up 47.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 earnings per share. View Exelixis' Earnings History.
When is Exelixis' next earnings date?
What price target have analysts set for EXEL?
11 Wall Street analysts have issued 1-year price objectives for Exelixis' stock. Their predictions range from $19.00 to $40.00. On average, they expect Exelixis' stock price to reach $30.00 in the next year. This suggests a possible upside of 69.1% from the stock's current price. View Analyst Price Targets for Exelixis.
What is the consensus analysts' recommendation for Exelixis?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.
What are Wall Street analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
- 1. According to Zacks Investment Research, "Exelixis' lead drug Cabometyx continues to perform well. Demand for the drug grew by approximately 30% sequentially in the first quarter driven by increases in new patient starts and refills for patients already on therapy. We expect sales to get a further boost in 2018 as the drug is now approved for first-line RCC which will increases the eligible patient population for Caobometyx in the United States by approximately 14,000 patients and grab market share from two key drugs — Sutent and Votrient in the first-line RCC market. A potential label expansion for advanced HCC will further boost the growth prospects of the drug. A label expansion of Cotellic will also boost sales. However, competition has further stiffened up with the recent approval of Opdivo and Yervoy for the treatment of poor and intermediate risk first-line RCC. Estimates are static ahead of Q2. Shares have underperformed the industry in the year so far." (7/31/2018)
- 2. Cann analysts commented, "We had anticipated a PDUFA date for this sNDA filing in H2 2018; as a result of the January 2019 PDUFA date we are slightly adjusting sales and EPS for 2018. Based on the timing of the PDUFA date, we are slightly delaying our estimated launch for Cabometyx in HCC. As a result we are decreasing our estimated 2018 revenue estimate by 3.5%, to $649.0 million from $672.8 million. We are reducing our estimated EPS in 2018 by 9.6%, to $0.67 from our prior estimate of $0.74. Our outlook for 2019 – 2022 revenue is unchanged." (5/30/2018)
Has Exelixis been receiving favorable news coverage?
Press coverage about EXEL stock has trended very positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Exelixis earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Are investors shorting Exelixis?
Exelixis saw a decrease in short interest in October. As of October 15th, there was short interest totalling 14,786,825 shares, a decrease of 13.4% from the September 28th total of 17,069,889 shares. Based on an average trading volume of 2,945,980 shares, the short-interest ratio is presently 5.0 days. Currently, 5.0% of the shares of the stock are sold short. View Exelixis' Current Options Chain.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI) and Dyadic International (DYAI).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 70)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 57)
- Mr. Christopher J. Senner, Exec. VP & CFO (Age 50)
- Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 57)
- Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 49)
Who are Exelixis' major shareholders?
Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.07%), FMR LLC (8.24%), JPMorgan Chase & Co. (1.98%), MERIAN GLOBAL INVESTORS UK Ltd (1.57%), First Trust Advisors LP (1.56%) and Renaissance Technologies LLC (1.37%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Which institutional investors are selling Exelixis stock?
EXEL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, Macquarie Group Ltd., Deutsche Bank AG, AQR Capital Management LLC, Allianz Asset Management GmbH, Handelsbanken Fonder AB and Handelsbanken Fonder AB. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Which institutional investors are buying Exelixis stock?
EXEL stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, BB Biotech AG, BlackRock Inc., MERIAN GLOBAL INVESTORS UK Ltd, American International Group Inc., JPMorgan Chase & Co., American Century Companies Inc. and Sofinnova Ventures Inc. View Insider Buying and Selling for Exelixis.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $17.74.
How big of a company is Exelixis?
Exelixis has a market capitalization of $5.36 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.51 on an earnings per share basis. Exelixis employs 372 workers across the globe.
What is Exelixis' official website?
How can I contact Exelixis?
Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
